Regulation of T cell homeostasis by heparan sulfate-bound IL-2

Journal of Immunology

Volumn 163, Issue 7, 1999, Pages 3793-3800

  Wrenshall, Lucile E ^a,c   Platt, Jeffrey L ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; INTERLEUKIN 2;

ANIMAL CELL; ARTICLE; AUTOIMMUNITY; BLOOD; CELL DEATH; CELL SURFACE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HOMEOSTASIS; LYMPHOCYTOSIS; LYMPHOID ORGAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SPLENOMEGALY; T LYMPHOCYTE;

ANIMALS; APOPTOSIS; CELL DIVISION; GLYCOSAMINOGLYCANS; HEPARAN SULFATE PROTEOGLYCANS; HEPARITIN SULFATE; HOMEOSTASIS; HUMANS; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; ORGAN SPECIFICITY; PROTEIN BINDING; T-LYMPHOCYTES;

EID: 0033215132     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Murdoch, A., G. Dodge, I. Cohen, R. Ruan, and R. Iozzo. 1992. Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG-2/perlecan). J. Biol. Chem. 267:8544.
2. Hovingh, P., M. Piepkorn, and A. Linker. 1986. Biological implications of the structural, antithrombin affinity and anticoagulant activity relationships among vertebrate heparins and heparan sulphates. Biochem. J. 237:573.
3. Toida, T., H. Yoshida, H. Toyoda, I. Koshiishi, T. Imanari, R. Hileman, J. Fromm, and R. Linhardt. 1997. Structural differences and the presence of unsubstituted amino groups in heparan sulphates from different tissues and species. Biochem. J. 322:499.
4. Webb, L., M. Ehrengruber, I. Clark-Lewis, M. Baggiolini. 1993. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc. Natl. Acad. Sci. USA 90:7158.
5. Bacon, K., B. Premack, P. Gardner, and T. Schall. 1995. Activation of dual T cell signaling pathways by the chemokine RANTES. Science 269:1727.
6. Sakata, H., S. Stahl, W. Taylor, J. Rosenberg, K. Sakaguchi, P. Wingfield, and J. Rubin. 1997. Heparin binding and oligomerization of hepatocyte growth factor/scatter factor isoforms. J. Biol. Chem. 272:9457.
7. Gordon, M., G. Rile, and S. Watt. 1987. Compartmentalization of a haemopoietic growth factor (GM-CSF) by glycosaminoglycans in the bone marrow microenvironment. Nature 326:403.
8. Roberts, R., E. Gallagher, and R. Spooncer. 1988. Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature 332:376.
9. Lortat-Jacob, H., P. Garrone, J. Banchereau, and J. Grimaud. 1997. Human interleukin 4 is a glycosaminoglycan-binding protein. Cytokine 9:101.
10. Lortat-Jacob, H., and J. Grimaud. 1991. Interferon-γ C-terminal function: new working hypothesis: heparan sulfate and heparin, new targets for IFN-γ, protect, relax the cytokine and regulate its activity. Cell. Mol. Biol. 37:253.
11. Clarke, D., O. Katoh, R. Gibbs, S. Griffiths, and M. Gordon. 1995. Interaction of interleukin 7 (IL-7) with glycosaminoglycans and its biological relevance. Cytokine 7:325.
12. Ramsden, L., and C. Rider. 1992. Selective and differential binding of interleukin (IL)-1∞, IL-1β, IL-2, and IL-6 to glycosaminoglycans. Eur. J. Immunol. 22:3027.
13. Goetzel, E., M. Banda, and D. Leppert. 1997. Matrix metalloproteases in immunity. J. Immunol. 156:1.
14. Fridman, R., O. Lider, Y. Naparstek, Z. Fuks, G. Korner, I. Vlodavski, and I. Cohen. 1987. Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparan sulfate moiety of subendothelial extracellular matrix. J. Cell. Physiol. 130:85.
15. Vilar, R., D. Ghael, M. Li, D. Bhagat, L. Arrigo, M. Cowman, H. Dweck, and L. Rosenfeld. 1997. Nitric oxide degradation of heparin and heparan sulphate. Biochemistry 324:473.
16. Key, N. S., J. L. Platt, and G. M. Vercellotti. 1992. Vascular endothelial cell proteoglycans are susceptible to cleavage by neutrophils. Arterioscler. Thromb. 12:836.
17. Graham, L. D., and P. A. Underwood. 1996. Comparison of the heparanase enzymes from mouse melanoma cells, mouse macrophages, and human platelets. Biochem. Mol. Biol. Int. 39:563.
18. Zhou, F. Y., R. T. Owens, J. Hermonen, M. Jalkanen, and M. Hook. 1997. Is the sensitivity of cells for FGF-1 and FGF-2 regulated by cell surface heparan sulfate proteoglycans? Eur. J. Cell. Biol. 73:166.
19. Gomez, J., A. Gonzalez, C. Martinez-A, and A. Rebollo. 1998. IL-2-induced cellular events. Crit. Rev. Immunol. 18:185.
20. 1/S transition to acquire susceptibility to fas-mediated apoptosis. J. Immunol. 157:4309.
21. s) gene expression. Eur. J. Immunol. 26:294.
22. van Parijs, L., A. Biuckians, A. Ibragimov, F. Alt, D. Willeford, and A. Abbas. 1997. Functional responses and apoptosis of CD25 (IL-2 Rα)-deficient T cells expressing a transgenic antigen receptor. J. Immunol. 158:3738.
23. Lenardo, M. 1991. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 353:858.
24. Kung, J., D. Beller, and S. Ju. 1998. Lymphokine regulation of activation-induced apoptosis in T cells of IL-2 and IL-2Rβ knockout mice. Cell. Immunol. 185:158.
25. Horak, I., J. Lohler, A. Ma, and K. Smith. 1995. Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol. Rev. 148:35.
26. Sgonc, R., and G. Wick. 1994. Methods for the detection of apoptosis. Int. Arch. Allergy Immunol. 105:327.
27. Ihrcke, N. and J. Platt. 1996. Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: evidence for proteolysis of cell-surface molecules. J. Cell. Physiol. 166:625.
28. Sekiguchi, R. T., S. Potter-Perigo, K. Braun, J. Miller, C. Ngo, K. Fukuchi, T. N. Wight, K. Kimata, and A. D. Snow. 1994. Characterization of proteoglycans synthesized by murine embryonal carcinoma cells (P19) reveals increased expression of perlecan (heparan sulfate proteoglycan) during neuronal differentiation. J. Neurosci. Res. 38:670.
29. Najjam, S., R. V. Gibbs, M. Y. Gordon, and C. C. Rider. 1997. Characterization of human recombinant interleukin 2 to heparin and heparan sulfate using an ELISA approach. Cytokine 9:1013.
30. Najjam, S., B. Mulloy, J. Theze, M. Gordon, R. Gibbs, and C. Rider. 1998. Further characterization of the binding of human recombinant interleukin 2 to heparin and identification of putative binding sites. Glycobiology 8:509.
31. Anderson, P., and M. Sorenson. 1994. Effects of route and formulation on clinical pharmacokinetics of interleukin-2. Clin. Pharmacokinet. 27:19.
32. Dohlsten, M., M. Bjorklund, A. Sundstedt, G. Hedlund, D. Samson, and T. Kalland. 1993. Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor Vβ transgenic mice. Immunology 79:520.
33. Willerford, D., J. Chen, J. Ferry, L. Davidson, A. Ma, and F. Art. 1995. Interleukin-2 receptor α chain regulated the size and content of the peripheral lymphoid compartment. Immunity 3:521.
34. Kneitz, B., T. Herman, S. Yonehara, and A. Schimpl. 1995. Normal clonal expansion but impaired Fas-mediated cell death and anergy in IL-2 deficient mice. Eur. J. Immunol. 25:2572.
35. Kearney, E., K. Pape, D. Loh, and M. Jenkins. 1994. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1:327.
36. Boehme, S. and M. Lenardo. 1993. Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. Eur. J. Immunol. 23:1552.
37. Smadja-Joffe, F., M. Moczar, C. Le Bousse-Kerdiles, B. Delpech, M. Leibovitch, F. Dufour, and C. Jasmin. 1992. Increased synthesis of extracellular spleen glycosaminoglycans in an experimental myeloproliferative syndrome. Leukemia 6:1011.
38. Hoogewerf, A., G. Kuschert, A. Proudfoot, F. Borlat, I. Clark-Lewis, C. Power, and T. Wells. 1997. Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochem. J. 36:13570.
39. Sadir, R., E. Forest, and H. Lortat-Jacob. 1998. The heparan sulfate binding sequence of interferon-γ increased the on rate of the interferon-γ-interferon-γ receptor complex formation. J. Biol. Chem. 273:10919.
40. Wrenshall, L., A. Carson, F. Cerra, and J. Platt. 1994. Modulation of cytolytic T cell responses by heparan sulfate. Transplantation 57:1087.
41. Wrenshall, L., F. Cerra, and A. Carlson. 1991. Regulation of murine splenocyte responses by heparan sulfate. J. Immunol. 147:455.
42. Wrenshall, L., F. Cerra, P. Rubenstein, and J. Platt. 1993. Regulation by heparan sulfate and IL-1α of the ontogenic expression of TcR, CD4, and CD8. Hum. Immunol. 38:165.
43. Mellemkjær, L., J. Olsen, M. Linet, G. Gridley, and J. McLaughlin. 1995. Cancer risk after splenectomy. Cancer 75:577.
44. Lynch, A., and R. Kapila. 1996. Overwhelming postsplenectomy infection. Infect. Dis. Clin. North Am. 10:693.
45. Sun, E., B. Vistica, D. Chan, J. Raber, I. Gery, and R. Nussenblatt. 1993. Splenectomy abrogates the induction of oral tolerance in experimental autoimmune uveoretinitis. Curr. Eye Res. 12:833.
46. Streilein, J., and J. Wiesner. 1977. Influence of splenectomy on first set rejection reactions of C57BL/6 females to male skin isografts. J. Exp. Med. 146:809.
47. Kelemen, E., P. Gergely, D. Lehoczky, E. Triska, J. Demeter, and P. Vargha. 1986. Permanent large granular lymphocytosis in the blood of splenectomized individuals without concomitant increase of in vitro natural killer cell cytotoxicity. Clin. Exp. Immunol. 63:696.
48. Doll, D. C., A. F. List, and J. W. Yarbro. 1987. Functional hyposplenism. South. Med. J. 80:999.
49. Wardrop, C. A., J. H. Dagg, F. D. Lee, H. Singh, J. F. Dyet, and A. Moffat. 1975. Immunological abnormalities in splenic atrophy. Lancet 2:4.
50. Chong, B. H., and M. Eisbacher. 1998. Pathophysiology and laboratory testing of heparin-induced thrombocytopenia. Semin. Hematol. 35:3.
51. van den Born, J., A. A. van Kraats, M. A. H. Bakker, K. J. M. Assmann, L. P. W. J. van den Heuvel, J. H. Veerkamp, and J. H. M. Berden. 1995. Selective proteinuria in diabetic nephropathy in the rat is associated with a relative decrease of glomerular basement membrane heparan sulphate. Diabetologia 38:161.
52. Sands, M., C. Vogler, A. Torrey, B. Levy, B. Gwynn, J. Grubb, W. Sly, and H. Birkenmeier. 1997. Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation. J. Clin. Invest. 99:1596.
53. Kisilevsky, R., L. Lemieux, P. Fraser, X. Kong, P. Hultin, and W. Szarek. 1995. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat. Med. 1:143.